Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Article
in En
| MEDLINE
| ID: mdl-31581306
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Biomarkers, Tumor
/
Antineoplastic Agents, Immunological
/
Inflammation
/
Antibodies, Monoclonal
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2020
Type:
Article